Plain-English translation of NCT07145411 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This trial offers access to Ossium HPC, Marrow — a bone marrow product prepared in a laboratory — for patients who need a bone marrow transplant. The medication is infused on the day of your transplant procedure. This is an expanded access program designed to help patients who cannot join other bone marrow transplant studies due to location or other eligibility reasons.
Not all patients who could benefit from this bone marrow product are able to participate in the main research study. This program exists to make the treatment available to more patients who have been approved by their doctors for bone marrow transplant and would benefit from it.
You likely qualify if…
You likely don't qualify if…
If you qualify, you would receive the laboratory-prepared bone marrow product through infusion on the day of your scheduled bone marrow transplant. Your care team will handle all preparation and medical oversight. This program is designed to provide you access to the treatment as part of your already-planned transplant procedure.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
United States
Sponsor
Ossium Health, Inc.
Enrollment target
~10 participants
Started
June 2024
Primary completion
August 2027
Age range
12 Years – 80 Years
Last updated on clinicaltrials.gov in August 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Preethi Prasad, Senior Director Clinical Operations
Ossium Health, Inc.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.